Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Pharmacokinetics of Paclitaxel in Rabbits with Carbon Tetrachloride-Induced Hepatic Failure

  • Published : 2002.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

The pharmacokinetic of paclitaxel (1 mg/kg, i.v.) was investigated in rabbits with carbon tetrachloride-induced hepatic failure. The area under the plasma concentration-time curve (AUC) of paclitaxel was significantly (p<0.01) increased in severe carbon tetrachloride-induced hepatic failure rabbits ($1364.54{\pm}382.07$ ng/ml$\cdot$hr) compared to that of normal rabbits ($567.52{\pm}141.88$ ng/ml$\cdot$hr), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits ($803.1{\pm}208.81$ ng/ml$\cdot$hr). The volume of distribution (Vd) (6.25$\pm$1.56 L) and the elimination rate constant($\beta$) ($0.09{\pm}0.025{\;}hr^{-1}$) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits were significantly (p<0.05) decreased compared to those of normal rabbits ($11.65<{\pm}2.91$L, $0.12{\pm}0.030{\;}hr^{-1}$), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits ($9.46{\pm}2.37$ L, $0.10{\pm}0.026{\;}hr^{-1}$). Total body clearance ($CL_t$) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits ($0.733{\pm}0.183$ L/hr/kg) was significantly (p<0.01) decreased compared to that of normal rabbits ($1.762{\pm}0.440$ L/hr/kg), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits ($1.245{\pm}0.311$ L/hr/kg). The half-life(t1/2) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits ($7.71{\pm}2.16$ hr) was significantly (p<0.05) increased compared to that of normal rabbits ($5.75{\pm}1.44$hr), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits ($6.77{\pm}1.76$hr). This results could be due to inhibition of paclitaxel metabolism in liver disorder rabbits since paclitaxel is essentially metabolized in liver. The findings suggest that the dosage regimen of paclitaxel should be adjusted when the drug would be administered in patients with liver disorder in a clinical situation.

Keywords

References

  1. Brenner, D. E., Wiernik, P. H., Wesley, M. and Bachur, N. R., Acute doxorubicin toxicity: Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer, 53, 1042-1048 (1984) https://doi.org/10.1002/1097-0142(19840301)53:5<1042::AID-CNCR2820530505>3.0.CO;2-B
  2. Brown, T., Havlin, K., Weiss, G., Cagnola, J., Koeller, J., Kuhn, J., Rizzo, J., Craig, J., Phillips, J. and Von Hoff, D., A Phasetrial of taxol given by a 6-hour intravenous infusion. J. Clin. Oncol., 9, 1261-1267 (1991) https://doi.org/10.1200/JCO.1991.9.7.1261
  3. Catalin, .J., Martin, N., Blachan, M. F. and Durand, A., Assay of paclitaxel (Taxol) in plasma and urine by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci., 709, 281-288 (1998) https://doi.org/10.1016/S0378-4347(98)00060-7
  4. Cresteil, T., Monsarrat, B., Alvinerie, P., Treluyer, J. M., Vieira, I. and Wright, M., Taxol metabolism by human liver microsomes: identifcation of cytochrome P450 isozymes involved in its biotramormation. Cancer. Res., 54, 386-392 (1994)
  5. Donel, M. G., Zucchetti, M., Munzone, E., Dlncalci, M. and Crosignani, A., Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur. J. Cancer., 34, 33-46 (1998) https://doi.org/10.1016/S0959-8049(97)00340-7
  6. Gianni L. Kearns, C., Giani, A., Capri, G., Vigano, L., Locatelli, A., Etonadonna, A. and Egorin, M., Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokineticl pha macodynarnic relationships in humans. J. Clin. Oncol., 13, 180-190 (1995) https://doi.org/10.1200/JCO.1995.13.1.180
  7. Grem, J.L., Tutsch, K.D., Simon, K.J., Alberti, D.B., Willson, J., Tormiey, D., Swaminathan, S. and Trump ,D., Phasestudy of taxol administered as a short iv infusion daily for 5 days. Cancer. Treat. Rep., 71, 1179-1184 (1987)
  8. Hirosh, F., Masaaki, O., Ayuko, T., Hideshi, M. and Hiroyuki, K., Pha macokinetics of Paclitaxel in experimental animals part 2. Tissue distribution. JPN. J. Cancer Chemother., 21, 659-664 (1994)
  9. Holmes, F. A., Walters, R. S., Theriault, R. L., Forman, A. D., Nevrton, L. K., Raber, M. N., Buzdar, A. U., Frye, D. K. and Hor obaqyi, G. N., Phase trial of taxol, an active drug in metastatic breast cancer. J. Natl. Cancer Inst., 83, 1797-1805 (1991)
  10. Kumar G N., Walle, U. K. and Walle, T., Cytochrome P450 3A-mec iated human liver microsomal taxol 6-hydroxylation. J. Pharmacol. Exp. Ther., 268, 1160-1165 (1994)
  11. Kumar N., Taxol-induced polymerization of purified tubulin. Mechanism of action. J. Biol. Chem., 256, 10435-10441 (1991)
  12. Manfe di, J. J. and Horwitz, S. B., An antimitotic agent with a new mechanism of action. Pharmacol. Ther. 25, 83-125 (1984) https://doi.org/10.1016/0163-7258(84)90025-1
  13. Mase, H., Hiraoka, M., Suzuki, A and Nakanomyo, H., Determination of New anticancer drug, Paclitaxel, in biological fluids by high performance liquid chromatography. Yakugaku Zasshi, 114, 351-355 (1994) https://doi.org/10.1248/yakushi1947.114.5_351
  14. McGui e, W. P., Rowinsky, E. K., Rosenheim, N. B., Grumbine, F. C., Ettinger, D. S. and Armstrong, D. K., Taxol: A unique antineoplasic agent with significant activity in advanced ovariar epithelial neoplasm. Ann. Intern. Med., 111, 273-279 (1999)
  15. Nannan F'anday, V. R., Huizing, M. T., Willemse, Pax H. B., De Graeff, A., ten Bokkel Huinink, W. W., Vermorken, J. B. and Beijnier , J. H., Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Sem. Oncol., 24(supol 11), S11-34-S11-38 (1997)
  16. Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalezs, F. J. and Haris, J. W., Selective biotransformation of taxol to 6-hydroxytaxol by human cytochrome P450 2C8. Cancer Res., 54. 5543-5546 (1994)
  17. Rowin sky E. K., Cazenave, L. A and Donehower, R.C., Taxol: A nove investigational antimicrotubule agent. J. Natl. Cancer Inst., 82, 1247-1259 (1990) https://doi.org/10.1093/jnci/82.15.1247
  18. Rowinsky, E., Eisenhauer, E., Chaudhry, V., Arbuck, S. G. and Donehower, R. C., Clinical toxicities encountered with paclitaxel (Taxol (R)). Sem. Oncol. 20 Suppl., 3, 1-15 (1993)
  19. Sarosy, G., Kohn, E., Stone, D. A., Rothenberg, M., Jacob, J., Adamo, D. O., Ognibene, F. P., Cunnion, R. E. and Reed, E., Phasestudy of taxol and granulocyte stimulating factor in patients with refractory ovarian cancer. J. Clin. Oncol. , 10, 1165-1170 (1992) https://doi.org/10.1200/JCO.1992.10.7.1165
  20. Sonnichsen, D. S., Liu Q, Schuetz. E, G., Schuetz, J. D., Pappo, A. and Reiling, M. V, Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther., 275, 566-575 (1995)
  21. Sonnichsen, D. S., Hurwitz, C. A, Pratt, C. B., Shuster, J. J. and Reiling, M. V., Saturable pharmacokinetics and paclitaxel pharmacodynamics in child with solid tumors. J. Clin. Oncol., 12, 532-538 (1994) https://doi.org/10.1200/JCO.1994.12.3.532
  22. Sparreboom, A., Van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K., Borst, P., Nooijen, W. J., Bejinen, J. H. and van Tellingen, O., Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by Pglycoprotein in the intestine. Proc. Natl. Acad. Sci. USA., 4, 2031-2035 (1997)
  23. Van den Berg, H. W., Desai, Z. R., Wilson, R., Kennedy, G., Bridges, J. M. and Shanks, R G., The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother. Pharmacol., 8, 215-219 (1982) https://doi.org/10.1007/BF00255487
  24. Venook, A. P., Egorin, M. J., Rosner, G. L., Brown, T. D., Jahan, T. M., Batist, G., Hohl, R., Budman, D., Ratain, M. J., Kearns, C. M. and Schilsky, R. L., Phase and pharmacokinetic trial of paciltaxel in patients with hepatic dysfunction: cancer and leukemia group B 9264. J. Clin. Oncol., 16, 1811-1819 (1998) https://doi.org/10.1200/JCO.1998.16.5.1811
  25. Wani, M. C., Taylor, H. L., Wall, M.E., Coggon, P. and McPhail, A. T., Plant antitumor agnets. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 93, 2325-2327 (1971) https://doi.org/10.1021/ja00738a045
  26. Walle, T., Walle, U. K., Kumar, G. N. and Bhalla, K. N., Taxol metabolism and disposition in cancer patients. Durg Metab. Disp., 23, 506-512 (1995)
  27. Wiernik, P., Schwartz, E., Einzig, A., Strauman, J., Dutcher, J. P. and Lipton, R. B., Phasetrial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J. Clin. Oncol., 5, 1232-1239 (1987) https://doi.org/10.1200/JCO.1987.5.8.1232
  28. Wiernik, P., Schwartz, E., Strauman, J., Dutcher, J. P., Lipton, R. B. and Paietta, E., Phaseclinical and pharmacokinetic study of taxol. Cancer Res., 47, 2486-2493 (1987)
  29. Yamaoka, K., Tanigawara, Y., Nakagawa, T. and Uno, T., A pharmacokinetics analysis program for microcomputer. J. Pharm. Dyn., 4, 879-883 (1981) https://doi.org/10.1248/bpb1978.4.879